Showing Results for
- Academic Journals (24)
Search Results
- 24
Academic Journals
- 24
- Search Terms:
- 1From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor Affiliations: Main The threat of losing market exclusivity for the blockbuster antiplatelet drug Plavix (clopidrogel), has suddenly turned into a reality for its co-marketers Bristol-Myers Squibb (BMS) and...
- 2From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor(s): Oleg V. Evgenov (corresponding author) [1, 2]; Pál Pacher [3]; Peter M. Schmidt [4, 5]; György Haskó [6]; Harald H. H. W. Schmidt [4, 5]; Johannes-Peter Stasch [7] Nitric oxide (NO) is a key signalling...
- 3From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor(s): Ezzie Hutchinson Imatinib mesylate (Gleevec) potently inhibits the kinase activity of the oncogenic fusion protein BCR-ABL and is an effective treatment for chronic myeloid leukaemia. Although imatinib seems...
- 4From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor(s): Charlotte Harrison Can a common single nucleotide polymorphism (SNP) have sufficient impact to affect therapeutic targeting in heart disease? This possibility has recently been raised in a paper by Liggett...
- 5From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedThe threat of losing market exclusivity for the blockbuster antiplatelet drug Plavix (clopidrogel), has suddenly turned into a reality for its co-marketers Bristol-Myers Squibb (BMS) and Sanofi-Aventis. The two companies...
- 6From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor(s): Richard E. T. Smith [1] The hepatitis C virus (HCV) is believed to have infected approximately 170 million people worldwide (Fig. 1). Often referred to as the silent killer, patients can remain asymptomatic...
- 7From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor(s): Bernard Munos [1] Open-source research, which started as a counterculture movement in the software industry 15 years ago, has since grown into a business model whose best-known product, Linux, has become a...
- 8From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor(s): Emma Marris With concerns over drying pipelines, patent expiries and plummeting stock prices, few people were surprised by the announcement that Pfizer's CEO, Henry A. 'Hank' McKinnell, is vacating the post...
- 9From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor(s): Boris Turk [1] Proteases, also known as proteolytic enzymes, are enzymes that catalyse the breakdown of proteins by hydrolysis of peptide bonds. Using bioinformatic analysis of the mouse and human genomes,...
- 10From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor Affiliations: Success uncertain for HIV vaccines Scientists unsure whether an HIV vaccine can ever be created. The lowdown: An HIV vaccine remains the best hope for combating the AIDS epidemic. But it is...
- 11From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor(s): Norman E. Sharpless [1]; Ronald A. DePinho [2] Since Richard Nixon declared a war on cancer in 1971, enormous resources -- more than US$200 billion by one estimate [1] -- have been invested in basic and...
- 12From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedRobert R. Ruffolo, Jr, President, Research and Development, and Corporate Vice President, Wyeth Pharmaceuticals [illus. 1] Robert R. Ruffolo joined Wyeth in 2000 as Executive Vice President, responsible for...
- 13From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor(s): Hagop Kantarjian [1]; Elias Jabbour [1]; Joanne Grimley [1]; Peter Kirkpatrick [1] Chronic myeloid leukaemia (CML) is a haematological stem-cell disorder that is characterized by excessive proliferation of...
- 14From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor(s): Akio Ohta [1]; Michail Sitkovsky [1] Dear Editor, Jacobson and Gao recently published an excellent overview of adenosine receptors as therapeutic targets [1]. In this commentary, we would like to...
- 15From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor(s): Alexandra Flemming The possible effects of stress on cancer are a matter of hot debate. While most studies investigating this connection focus on the dampening effects of stress on the immune response to...
- 16From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedMuch of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromolecules by low-molecular-mass drugs. The binding of drugs to their macromolecular targets is therefore seen...
- 17From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedObesity Neuronal PTP1B regulates body weight, adiposity and leptin action . Bence, K. K. et al . Nature Med. 16 July 2006 (doi:10.1038/mm1435) Protein tyrosine phosphatase (PTP) 1B is a potential therapeutic...
- 18From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor(s): Katherine Whalley The idea that endogenous progenitor cells might be harnessed to replace neurons lost in neurodegenerative diseases is popular, but requires the development of methods to stimulate their...
- 19From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedThirty-five years have passed since a 'war on cancer' was declared, but despite billions of dollars of investment, decisive victory is still distant. However, with limitations in standard development strategies for...
- 20From: Nature Reviews Drug Discovery. (Vol. 5, Issue 9) Peer-ReviewedAuthor(s): Steve C.F. Au-Yeung [1]; Patrick S.K. Pang [1, 2]; Yee-ping Ho [2] The recent review by Wang and Lippard [1] raises the issue of whether the current trend of shifting away from the development of effective...